SangStat Bets on Focus vs. Size
Up against Novartis, the Swiss marketing giant that now owns the $1.3 billion market for cyclosporine, SangStat insists that its disease management approach to organ transplantation is the right model at the right time.
You may also be interested in...
The transplantation market has changed considerably since Novartis (via its predecessor, Sandoz) launched the then-revolutionary selective immunosuppressant cyclosporin in 1983. Nowadays, clinicians and patients have many more treatment options--thanks largely to enhanced understanding of immunology--and thus the trend is strongly towards individualized therapy. In response to this shift, Novartis has given up pursuing radically new approaches to treatment and is concentrating on developing a product for every class of drug now used to treat graft recipients.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.